Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Oncologia Medica
Welcome,         Profile    Billing    Logout  
 0 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tambaro, Rosa
NCT05024773 / 2022-001236-28: Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Recruiting
3
112
Europe, US
ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
Fidia Farmaceutici s.p.a.
Bladder Carcinoma in Situ (CIS)
11/25
11/27
GDFather-NEO, NCT06059547 / 2022-002816-22: Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

Active, not recruiting
2
30
Europe
Nivolumab, Visugromab (CTL-002), Placebo
CatalYm GmbH, CatalYm GmbH
Bladder Cancer, Adult Solid Tumor
08/25
09/26
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
Iacovelli, Roberto
SELECTIO-UC, NCT06820255: DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

Recruiting
4
135
Europe
Platinum + Gemcitabine, Avelumab first-line maintenance, NGS test for DDR alterations
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable, Upper Tract Urothelial Cancer
01/26
01/27
ITALIC-RCC, NCT06903312: Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.

Not yet recruiting
4
409
NA
Deferred Cytoreductive Nephrectomy + medical treatment, Radiotherapy + medical treatment, Medical therapy, Standard of Care (SOC)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, AIRC (Italian Association for Cancer Research)
Renal Cell Cancer, Kidney Neoplasm, Immunotherapy, Kidney Cancer, Surgery Programmed, Radiotherapy
10/27
04/28
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
400
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Recruiting
3
300
Europe
Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT
UNICANCER, Bayer
Prostate Cancer Metastatic
03/28
09/37
TIDE-A, NCT04698213: Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

Recruiting
2
75
Europe
Axitinib Oral Tablet, Avelumab
Consorzio Oncotech, Clinical Research Technology S.r.l.
Renal Carcinoma Metastatic
09/23
10/24
CNN-BC, NCT05203913: Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer

Recruiting
2
32
Europe
Nivolumab, Opdivo, Nab paclitaxel, Abraxane, Cisplatin, CDDP, Radiotherapy, RT
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Muscle-Invasive Bladder Carcinoma
12/25
06/26
GDFather-NEO, NCT06059547 / 2022-002816-22: Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

Active, not recruiting
2
30
Europe
Nivolumab, Visugromab (CTL-002), Placebo
CatalYm GmbH, CatalYm GmbH
Bladder Cancer, Adult Solid Tumor
08/25
09/26
PE-PE, NCT05578664 / 2022-001077-30: Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer

Recruiting
2
81
Europe
Pembrolizumab injection plus metastasis directed treatment (surgery or RT), Tumor resection or RT
Consorzio Oncotech, MERCK SHARP & DOHME LLC.
Oligometastatic Renal Cell Carcinoma
10/24
10/25
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Urothelial Carcinoma
12/26
06/28
AxIn, NCT05817903 / 2022-001150-35: Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Recruiting
2
118
Europe
Axitinib, Inlyta, Nivolumab
Consorzio Oncotech, Pfizer
Metastatic Renal Cell Carcinoma
04/26
04/27
SkinHealthOnco, NCT05878964: Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.

Recruiting
N/A
420
Europe
EQ-5D-5L questionnaire, FACT-G (Functional Assessment of Cancer Therapy - General), FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lung Cancer, Breast Cancer, Kidney Cancer, Bladder Cancer, Gastric Cancer, Skin Cancer, Melanoma, Head Neck Cancer
07/25
09/25
PSA-DEEP02, NCT06652607: PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

Recruiting
N/A
152
Europe
Enzalutamide, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Taxotere (docetaxel), Abiraterone acetate + Prednisone or Prednisolone
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prostate Cancer, Metastatic Cancer, Castrate Sensitive Prostate Cancer
11/26
04/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tambaro, Rosa
NCT05024773 / 2022-001236-28: Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Recruiting
3
112
Europe, US
ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
Fidia Farmaceutici s.p.a.
Bladder Carcinoma in Situ (CIS)
11/25
11/27
GDFather-NEO, NCT06059547 / 2022-002816-22: Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

Active, not recruiting
2
30
Europe
Nivolumab, Visugromab (CTL-002), Placebo
CatalYm GmbH, CatalYm GmbH
Bladder Cancer, Adult Solid Tumor
08/25
09/26
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
Iacovelli, Roberto
SELECTIO-UC, NCT06820255: DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

Recruiting
4
135
Europe
Platinum + Gemcitabine, Avelumab first-line maintenance, NGS test for DDR alterations
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable, Upper Tract Urothelial Cancer
01/26
01/27
ITALIC-RCC, NCT06903312: Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.

Not yet recruiting
4
409
NA
Deferred Cytoreductive Nephrectomy + medical treatment, Radiotherapy + medical treatment, Medical therapy, Standard of Care (SOC)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, AIRC (Italian Association for Cancer Research)
Renal Cell Cancer, Kidney Neoplasm, Immunotherapy, Kidney Cancer, Surgery Programmed, Radiotherapy
10/27
04/28
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
400
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Recruiting
3
300
Europe
Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT
UNICANCER, Bayer
Prostate Cancer Metastatic
03/28
09/37
TIDE-A, NCT04698213: Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

Recruiting
2
75
Europe
Axitinib Oral Tablet, Avelumab
Consorzio Oncotech, Clinical Research Technology S.r.l.
Renal Carcinoma Metastatic
09/23
10/24
CNN-BC, NCT05203913: Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer

Recruiting
2
32
Europe
Nivolumab, Opdivo, Nab paclitaxel, Abraxane, Cisplatin, CDDP, Radiotherapy, RT
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Muscle-Invasive Bladder Carcinoma
12/25
06/26
GDFather-NEO, NCT06059547 / 2022-002816-22: Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

Active, not recruiting
2
30
Europe
Nivolumab, Visugromab (CTL-002), Placebo
CatalYm GmbH, CatalYm GmbH
Bladder Cancer, Adult Solid Tumor
08/25
09/26
PE-PE, NCT05578664 / 2022-001077-30: Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer

Recruiting
2
81
Europe
Pembrolizumab injection plus metastasis directed treatment (surgery or RT), Tumor resection or RT
Consorzio Oncotech, MERCK SHARP & DOHME LLC.
Oligometastatic Renal Cell Carcinoma
10/24
10/25
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Urothelial Carcinoma
12/26
06/28
AxIn, NCT05817903 / 2022-001150-35: Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Recruiting
2
118
Europe
Axitinib, Inlyta, Nivolumab
Consorzio Oncotech, Pfizer
Metastatic Renal Cell Carcinoma
04/26
04/27
SkinHealthOnco, NCT05878964: Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.

Recruiting
N/A
420
Europe
EQ-5D-5L questionnaire, FACT-G (Functional Assessment of Cancer Therapy - General), FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lung Cancer, Breast Cancer, Kidney Cancer, Bladder Cancer, Gastric Cancer, Skin Cancer, Melanoma, Head Neck Cancer
07/25
09/25
PSA-DEEP02, NCT06652607: PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

Recruiting
N/A
152
Europe
Enzalutamide, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Taxotere (docetaxel), Abiraterone acetate + Prednisone or Prednisolone
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prostate Cancer, Metastatic Cancer, Castrate Sensitive Prostate Cancer
11/26
04/28

Download Options